

Date: February 08, 2023

To,
The Deputy Gen. Manager,
Metropolitan Stock Exchange of India Ltd
Vibgyor Towers, 4th Floor, Plot No. C-62,
G-Block, Opp. Trident, Bandra-Kurla Complex,
Bandra (E), Mumbai-400 098

Dear Sir / Madam,

Sub: Outcome of Board Meeting of Jagadishwar Pharmaceutical Works Limited held on February 08, 2023

Ref: Regulation 33 (3) of SEBI (Listing Obligation and Disclosures Requirements) Regulations 2015

With reference to the above captioned subject, outcome of the meeting of the Board of Directors of Jagadishwar Pharmaceutical Works Limited which was held today at 2.30 p.m. and concluded at 3.00 p.m. is as follows:

Approved Unaudited Financial Results of the Company for the quarter ended December 31, 2022 were considered and approved by the Board.

Find enclosed herewith a copy of Unaudited Financial Results along with Limited Review Report pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

You are requested to take note of the same.

Thanking You,

Yours Faithfully,
For Jagadishwar Pharmaceutical Works Limited

Swapan Sarkar
Director
DIN: 05149442

Encl: As above

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232AS1987PLC002803)

Regd Office: 205, Haribol Roy Market, A.T.Road, 2nd Floor, Near Saraf Building, Guwahati - 781 001

Corp. Office : 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Email: jpw ltd@yahoo.com, **Website:** jagadishwarpharma.com, **Tel.:** +91 9163513015


UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2022

	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-03-2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income From Operations	-	-	1.85	-	1.85	1.85
II	Other Income	8.76	8.62	11.53	28.39	31.16	50.61
III	Total Income from operations (I + II)	8.76	8.62	13.37	28.39	33.01	52.46
IV	Expenses						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	3.04
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	1.85	-	1.85	(1.19)
	(d) Employee benefits expense	5.54	8.93	6.00	19.61	20.07	20.19
	(e) Depreciation and amortisation expense	-	-	-	-	-	-
	(f) Finance Cost	-	-	-	-	-	-
	(g) Other expenses	2.07	1.85	1.86	8.48	8.26	10.81
	Total Expenses	7.61	10.78	9.70	28.09	30.18	32.85
V	Profit (Loss) before exceptional items and extraordinary items and tax (III-IV)	1.15	(2.16)	3.67	0.30	2.83	19.61
VI	Exceptional Items	-	-	-	-	-	6.84
VII	Profit from ordinary activities before finance costs and Exceptional Items (V-VI)	1.15	(2.16)	3.67	0.30	2.83	12.76
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	Net Profit/(Loss) before tax (VII-VIII)	1.15	(2.16)	3.67	0.30	2.83	12.76
X	Tax Expense :						
	(1) Current Tax	-	-	1.15	-	-	3.38
	(2) Deferred Tax	-	-	-	-	-	-
	Total Tax Expenses	-	-	1.15	-	-	3.38
XI	Net Profit/(Loss) for the period from continuing operations (IX-X)	1.15	(2.16)	2.52	0.30	2.83	9.38
XII	Profit/(Loss) for the period from discontinuing operations	-	-	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(Loss) for the period from discontinuing operations (after tax)	-	-	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	1.15	(2.16)	2.52	0.30	2.83	9.38
XVI	Other Comprehensive Income	-	-	-	-	-	(6.37)
XVII	Total Comprehensive Income	1.15	(2.16)	2.52	0.30	2.83	3.01
XVIII	Paid up Equity Share Capital (Face Value of Rs.10/- per Share)	2,970.02	2,970.02	2,970.02	2,970.02	2,970.02	2,970.02
XVIX	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	112.66
XX	Earnings Per Share (EPS)						
	(a) Basic	0.00	-	0.00	0.00	0.00	0.00
	(b) Diluted	0.00	-	0.00	0.00	0.00	0.00

Notes:

- 1 The above results have been reviewed by the audit committee and approved by the Board of Directors of the Company in its meeting held on 8th February, 2023.
- 2 The standalone financial results of the Company for the quarter and nine months ended 31st December, 2022 have been unaudited by the Statutory Auditors.
- 3 Statutory Auditors have carried out a "Limited Review" of the above financial results for the quarter/nine months ended 31st December, 2022.
- 4 Previous Period / Year figures have been regrouped/reclassified to make them comparable with those of current period/year.

For Jagadishwar Pharmaceutical Works Limited


 Swapan Sarkar
 Director
 (DIN: 05149442)

Place : Kolkata
Date : 08.02.2023

LIMITED REVIEW REPORT

To
The Board of Directors,
Jagadishwar Pharmaceutical Works Limited

We have reviewed the unaudited financial results of **Jagadishwar Pharmaceutical Works Limited** (“the Company”), for the quarter ended December 31, 2022 together with the notes thereon (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations, 2015”), Which has been initialed by us for identification purposes. The Statement is the responsibility of the Company’s management and has been approved by the Board of Directors. Further, the management is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent with those used in the preparation of the Company’s opening unaudited Balance Sheet as at April 01, 2016 prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim financial information performed by the independent auditor of the entity” issues by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.


Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practiced and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We draw attention to the following matters:

- a) Note 2 to the Statement which states that the Company has adopted Ind AS for the financial year commencing from April 1, 2022, and accordingly, the Statement has been prepared by the Company’s Management in compliance with Ind AS.
- b) We were neither engaged to review, nor have we review, nor have we reviewed the comparative figures including reconciliation to the Total Comprehensive Income for the quarter ended on December 31, 2022. As set out in note 5 to the Statement, these figures have been furnished by the Management.

Place : Kolkata
Date : 8th February, 2023

For **S. N. Chakrabarty & Co.**
Chartered Accountants



S. N. Chakrabarty
(Proprietor)
Membership No : 016230
Firm Regn. No.: 309080E
UDIN : 23016 230362010 2542